A Prospective Non-Interventional Study to Describe the Effectiveness and Safety of Venetoclax as a First-Line Treatment in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible to Intensive Chemotherapy in Routine Clinical Practice in Greece
Latest Information Update: 29 Jul 2025
At a glance
- Drugs Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms SURVIVE
- Sponsors AbbVie
Most Recent Events
- 16 Jul 2025 Planned End Date changed from 31 Dec 2026 to 1 Dec 2026.
- 16 Jul 2025 Planned primary completion date changed from 31 Dec 2026 to 1 Dec 2026.
- 26 Jan 2023 Planned primary completion date changed from 30 May 2026 to 31 Dec 2026.